Source
Rare Disease Advisor
Cardiac amyloidosis (CA) is present in approximately 10% of patients with heart failure worldwide, with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) accounting for the majority of cases, according to a recent study preprint on Research Square.
CA is an infiltrative cardiomyopathy caused by extracellular deposition of misfolded amyloid proteins in the heart and is a more common contributor to heart failure than previously thought, especially with advances in noninvasive diagnostics like technetium-labeled bone scintigraphy.
News Url